Abstract:Background: Invasive fungal infection is an important cause of mortality and morbidity in very low birth weight infants. Early diagnosis is difficult and treatment is often delayed. Systemic antifungal agents (usually azoles) are increasingly used as prophylaxis against invasive fungal infection. Objectives: To assess the effect of prophylactic systemic antifungal therapy on mortality and morbidity in very low birth weight infants. Search methods: We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 3), MEDLINE, EMBASE, and CINAHL (to August 2012), conference proceedings, and previous reviews. Selection criteria: Randomised controlled trials or quasi-randomised controlled trials that compared the effect of prophylactic systemic antifungal therapy versus placebo or no drug or another antifungal agent or dose regimen in very low birth weight infants. Data collection and analysis: We extracted data using the standard methods of the Cochrane Neonatal Review Group, with separate evaluation of trial quality and data extraction by two review authors. Main results: We identified 11 eligible trials enrolling a total of 1136 infants. Seven trials (involving 880 infants) compared systemic antifungal prophylaxis versus placebo or no drug. These trials were generally small but of good methodological quality. Meta-analysis found a statistically significant reduction in the incidence of invasive fungal infection in infants who received systemic antifungal prophylaxis (typical risk ratio (RR) 0.41, 95% confidence interval (CI) 0.27 to 0.61; risk difference (RD) -0.09, 95% CI -0.14 to -0.05). The average incidence of invasive fungal infection in the control groups of the trials (16%) was much higher than that generally reported from large cohort studies (< 5%). Meta-analysis did not find a statistically significant difference in the risk of death prior to hospital discharge (typical RR 0.74, 95% CI 0.52 to 1.05; RD -0.04, 95% CI -0.08 to 0.01). Very limited data on long-term neurodevelopmental outcomes were available. Two trials that compared systemic versus oral or topical non-absorbed antifungal prophylaxis did not detect any statistically significant effects on invasive fungal infection or mortality. Two trials that compared different dose regimens of prophylactic intravenous fluconazole did not detect any significant differences in infection rates or mortality. Authors' conclusions: Prophylactic systemic antifungal therapy reduces the incidence of invasive fungal infection in very low birth weight infants. This finding should be interpreted and applied cautiously since the incidence of invasive fungal infection was very high in the control groups of most of the included trials. Meta-analysis does not demonstrate a statistically significant effect on mortality. There are currently only limited data on the long-term neurodevelopmental consequences for infants exposed to this intervention. In addition, there is a need for further data on the effect of the intervention on the emergence of organisms with antifungal resistance.

Antifungal Drug Usage in European Neonatal Units: A Multicenter Weekly Point Prevalence Study

Clinical Significance of Oral Fluconazole Prophylaxis Against Invasive Fungal Infection in Preterm Neonates with Peripherally Inserted Central Catheters

Risk Factors and Clinical Analysis for Invasive Fungal Infection in Neonatal Intensive Care Unit Patients

Clinical characteristic analysis for invasive fungal infection in neonatal intensive care unit

Invasive Candida Infections in Neonatal Intensive Care Units: Risk Factors and New Insights in Prevention

Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants

Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study

Antibiotics and antifungals in neonatal intensive care units: a review

Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial

Ototoxic and nephrotoxic drugs in neonatal intensive care units: results of a Spanish and Italian survey

Nebulization of Antimicrobial Agents in Mechanically Ventilated Adults in 2017: an International Cross-Sectional Survey

Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population

Diuretic drug utilization in neonates: a French prescription database analysis

Clinical Characteristic and Antifungal Drug Sensitivity of Candida Parapsilosis Infections in Blood of Neonates

Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps

Antimicrobial Resistance Pattern and Empirical Antibiotic Treatments in Neonatal Sepsis: A Retrospective, Single-Center, 12-Year Study

Neonatal Fungemia by Non-Candida Rare Opportunistic Yeasts: A Systematic Review of Literature

Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice

Five-Year Evaluation of the PROA-NEN Pediatric Antimicrobial Stewardship Program in a Spanish Tertiary Hospital

Neonatal ICU antibiotic use trends within an integrated delivery network

Spanish Society of Hospital Pharmacy and the Spanish Society of Pediatric Infectious Diseases (SEFH-SEIP) National Consensus Guidelines for therapeutic drug monitoring of antibiotic and antifungal drugs in pediatric and newborn patients